The Jab: Why can’t more be made?
Listen now
Description
Thousands are dying each day amid vaccine shortages. Would a patent waiver save lives? Jayati Ghosh of the University of Massachusetts Amherst says liberating IP is an urgent moral issue. Richard Hatchett, CEO at CEPI, disagrees. Alok Jha and Natasha Loder are joined by Edward Carr, our deputy editor, and economics columnist Ryan Avent. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts   See acast.com/privacy for privacy and opt-out information.
More Episodes
Published 06/28/21
Vaccines are helping some countries return to a semblance of normalcy, while much of the world remains vulnerable to covid-19. We explore what’s next for the pandemic at this critical juncture. Soumya Swaminathan, Chief Scientist at the World Health Organisation, says solidarity has been lacking...
Published 06/28/21
The first covid-19 vaccines came from rapid innovation. They have already saved millions of lives. What new technologies are in the pipeline?   Robin Shattock’s team at Imperial College London is developing a self-amplifying RNA vaccine.   Moz Siddiqui of Gavi, the Vaccine Alliance, describes a...
Published 06/21/21